AxoGen (AXGN) Competitors $10.98 +0.05 (+0.41%) As of 10:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AXGN vs. NVCR, WRBY, SSII, CNMD, LMAT, TNDM, EYE, CDRE, LQDA, and AORTShould you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include NovoCure (NVCR), Warby Parker (WRBY), SS Innovations International (SSII), CONMED (CNMD), LeMaitre Vascular (LMAT), Tandem Diabetes Care (TNDM), National Vision (EYE), Cadre (CDRE), Liquidia (LQDA), and Artivion (AORT). These companies are all part of the "medical equipment" industry. AxoGen vs. NovoCure Warby Parker SS Innovations International CONMED LeMaitre Vascular Tandem Diabetes Care National Vision Cadre Liquidia Artivion NovoCure (NASDAQ:NVCR) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, community ranking, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Does the MarketBeat Community believe in NVCR or AXGN? NovoCure received 20 more outperform votes than AxoGen when rated by MarketBeat users. However, 72.93% of users gave AxoGen an outperform vote while only 62.98% of users gave NovoCure an outperform vote. CompanyUnderperformOutperformNovoCureOutperform Votes47862.98% Underperform Votes28137.02% AxoGenOutperform Votes45872.93% Underperform Votes17027.07% Which has more risk & volatility, NVCR or AXGN? NovoCure has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Do institutionals & insiders hold more shares of NVCR or AXGN? 84.6% of NovoCure shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 6.3% of NovoCure shares are held by insiders. Comparatively, 2.8% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is NVCR or AXGN more profitable? AxoGen has a net margin of -7.91% compared to NovoCure's net margin of -25.93%. AxoGen's return on equity of -14.91% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets NovoCure-25.93% -41.48% -12.74% AxoGen -7.91%-14.91%-7.49% Which has preferable valuation and earnings, NVCR or AXGN? AxoGen has lower revenue, but higher earnings than NovoCure. AxoGen is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovoCure$621.71M3.24-$207.04M-$1.51-11.98AxoGen$194.52M2.57-$21.72M-$0.15-73.23 Do analysts rate NVCR or AXGN? NovoCure currently has a consensus target price of $32.83, suggesting a potential upside of 81.54%. AxoGen has a consensus target price of $22.20, suggesting a potential upside of 102.09%. Given AxoGen's stronger consensus rating and higher probable upside, analysts plainly believe AxoGen is more favorable than NovoCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67AxoGen 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor NVCR or AXGN? In the previous week, NovoCure had 4 more articles in the media than AxoGen. MarketBeat recorded 8 mentions for NovoCure and 4 mentions for AxoGen. NovoCure's average media sentiment score of 1.36 beat AxoGen's score of 0.67 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAxoGen beats NovoCure on 10 of the 18 factors compared between the two stocks. Get AxoGen News Delivered to You Automatically Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXGN vs. The Competition Export to ExcelMetricAxoGenElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$504.90M$3.13B$5.31B$8.28BDividend YieldN/A1.72%5.20%4.10%P/E Ratio-34.6416.9526.7319.58Price / Sales2.5795.82387.44119.65Price / CashN/A44.0938.2534.62Price / Book4.953.716.744.47Net Income-$21.72M$94.03M$3.23B$248.22M7 Day Performance-7.14%-0.27%-0.05%-1.32%1 Month Performance-29.67%18.50%8.51%10.73%1 Year Performance79.79%-9.88%18.25%8.40% AxoGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXGNAxoGen3.2587 of 5 stars$10.99+0.4%$22.20+102.1%+76.5%$504.90M$194.52M-34.64450NVCRNovoCure3.5988 of 5 stars$18.57+6.8%$32.83+76.8%-23.6%$2.07B$621.71M-13.261,320Positive NewsGap UpWRBYWarby Parker3.083 of 5 stars$18.88+19.9%$22.21+17.6%+19.6%$1.97B$795.09M-69.943,030Analyst ForecastAnalyst RevisionHigh Trading VolumeSSIISS Innovations InternationalN/A$10.15+0.6%N/AN/A$1.96B$20.65M0.004High Trading VolumeCNMDCONMED4.5086 of 5 stars$60.75+6.4%$62.20+2.4%-25.1%$1.88B$1.32B14.334,100Positive NewsDividend AnnouncementLMATLeMaitre Vascular2.588 of 5 stars$82.46+2.7%$98.14+19.0%-1.1%$1.86B$226.26M45.06490Insider TradeTNDMTandem Diabetes Care4.4326 of 5 stars$23.45+2.0%$39.81+69.8%-59.8%$1.56B$982.95M-12.152,600Positive NewsAnalyst ForecastGap UpEYENational Vision2.7575 of 5 stars$18.76+9.3%$17.57-6.3%+22.0%$1.48B$1.82B-93.8014,000Positive NewsHigh Trading VolumeCDRECadre3.6121 of 5 stars$35.75+1.0%$37.00+3.5%+4.1%$1.45B$559.81M43.072,240LQDALiquidia3.4781 of 5 stars$15.75+3.2%$27.13+72.2%+18.5%$1.35B$14.00M-9.6650Analyst ForecastGap UpAORTArtivion2.3499 of 5 stars$28.79-0.4%$31.40+9.1%+19.4%$1.23B$390.08M-1,439.351,300Insider Trade Related Companies and Tools Related Companies NVCR Alternatives WRBY Alternatives SSII Alternatives CNMD Alternatives LMAT Alternatives TNDM Alternatives EYE Alternatives CDRE Alternatives LQDA Alternatives AORT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AXGN) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AXGN Stock Free AXGN Stock Alerts